Literature DB >> 28571128

Association Between Serum Cystatin C and Creatinine in Chronic Kidney Disease Subjects Attending a Tertiary Health Care Centre.

Janice DSa1, Sukanya Shetty2, Roopa Rani Bhandary3, Ashalatha V Rao4.   

Abstract

INTRODUCTION: Chronic Kidney Disease (CKD) is an emerging health problem due to the increasing prevalence of conditions like diabetes mellitus and hypertension. Most patients are diagnosed during the later stages of CKD when the clinical symptoms become apparent. There is a need for early diagnosis to prevent disease progression and associated morbidities. Serum Creatinine (SCr) is commonly used among clinicians to determine renal function. However, SCr is affected by several factors and cannot be entirely relied upon. In pursuit of an alternative indicator of renal function, several biomarkers have been discovered and their utility in prompt diagnosis has been evaluated. Among such biomarkers, serum cystatin C (SCysC) has been extensively studied. AIM: To determine and compare the levels of SCr and SCysC in CKD subjects across various severity groups based on estimated Glomerular Filtration Rate (eGFR).
MATERIALS AND METHODS: The study comprised of 120 CKD subjects. SCr was estimated by modified Jaffe's method and SCysC was estimated by particle enhanced immunoturbidimetric method. Estimated GFR (eGFR) was determined using Chronic Kidney Disease Epidemiology collaboration (CKD EPI) 2009 creatinine based formula. Based on eGFR, CKD subjects were further categorized into four groups. Statistical analysis was done using SPSS. Data were represented as median and interquartile range. Kruskal Wallis test was used for comparison between more than two groups. Correlation was done using Pearson's test. Statistical significance was considered as p <0.05.
RESULTS: Both SCr and SCysC levels increased significantly across CKD groups (p<0.001). In CKD subjects with eGFR ≥ 60 ml/min/1.732 m2, the median value of SCr (1.01 mg/dl) was well within the normal range while median value of SCysC (1.34 mg/l) was found to be more than the upper reference limit. A positive correlation was present between SCysC and SCr (r=0.875, p<0.001). Both SCysC (r=-0.736) and SCr (r=-0.719) had a negative correlation with eGFR (p<0.001).
CONCLUSION: SCysC is useful in detecting individuals with CKD having mild decrease in GFR compared to SCr. Both SCr and SCysC levels increase with decrease in eGFR. SCysC may be used to screen patients with poorly controlled diabetes mellitus or hypertension when SCr level is inconclusive.

Entities:  

Keywords:  Glomerular filtration; Nephropathy; Renal function

Year:  2017        PMID: 28571128      PMCID: PMC5449774          DOI: 10.7860/JCDR/2017/26655.9655

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  15 in total

1.  Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients.

Authors:  L Risch; R Herklotz; A Blumberg; A R Huber
Journal:  Clin Chem       Date:  2001-11       Impact factor: 8.327

2.  Impact of thyroid dysfunction on serum cystatin C.

Authors:  Manuel Fricker; Peter Wiesli; Michael Brändle; Beat Schwegler; Christoph Schmid
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

3.  Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate.

Authors:  J Kyhse-Andersen; C Schmidt; G Nordin; B Andersson; P Nilsson-Ehle; V Lindström; A Grubb
Journal:  Clin Chem       Date:  1994-10       Impact factor: 8.327

4.  Diagnostic performance of serum cystatin C and serum creatinine in the prediction of chronic kidney disease in renal transplant recipients.

Authors:  J-P Tsai; S-W Wu; T-W Hung; W-T Kao; C-L Hong; J-D Lian; H-R Chang
Journal:  Transplant Proc       Date:  2010-12       Impact factor: 1.066

5.  Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate.

Authors:  Wolfgang Koenig; Dorothee Twardella; Hermann Brenner; Dietrich Rothenbacher
Journal:  Clin Chem       Date:  2004-11-24       Impact factor: 8.327

Review 6.  Cystatin C: a promising marker and predictor of impaired renal function.

Authors:  Justin Westhuyzen
Journal:  Ann Clin Lab Sci       Date:  2006       Impact factor: 1.256

7.  National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors:  Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

8.  Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function.

Authors:  Radovan Hojs; Sebastjan Bevc; Robert Ekart; Maksimiljan Gorenjak; Ludvik Puklavec
Journal:  Nephrol Dial Transplant       Date:  2006-03-08       Impact factor: 5.992

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

Review 10.  Cystatin C--properties and use as diagnostic marker.

Authors:  A O Grubb
Journal:  Adv Clin Chem       Date:  2000       Impact factor: 5.394

View more
  2 in total

1.  Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease.

Authors:  Tatsuki Ichikawa; Hisamitsu Miyaaki; Satoshi Miuma; Yasuhide Motoyoshi; Mio Yamashima; Shinobu Yamamichi; Makiko Koike; Youichi Takahashi; Tetsurou Honda; Hiroyuki Yajima; Ryouhei Uehara; Naoyuki Hino; Ryousuke Hirata; Naota Taura; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2020-01-24

2.  Machine Learning to Compare Frequent Medical Problems of African American and Caucasian Diabetic Kidney Patients.

Authors:  Yong-Mi Kim; Pranay Kathuria; Dursun Delen
Journal:  Healthc Inform Res       Date:  2017-10-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.